Reference : Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in alb...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/2077
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
English
Mogensen, Carl Erik [> > > >]
Viberti, Giancarlo [> > > >]
Halimi, Serge [> > > >]
Ritz, Eberhard [> > > >]
Ruilope, Luis [> > > >]
Jermendy, Gyorgy [> > > >]
Widimsky, Jiri [> > > >]
Sareli, Pinchas [> > > >]
Taton, Jan [> > > >]
Rull, Juan [> > > >]
Erdogan, Gurbuz [> > > >]
De Leeuw, Pieter W [> > > >]
Ribeiro, Arthur [> > > >]
Sanchez, Ramiro [> > > >]
Mechmeche, Rachid [> > > >]
Nolan, John [> > > >]
Sirotiakova, Jana [> > > >]
Hamani, Ahmed [> > > >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Hess, Bernhard [> > > >]
Luger, Anton [> > > >]
Thomas, Stephen M [> > > >]
2003
Hypertension
American Heart Association
41
5
1063-71
Yes (verified by ORBi)
International
0194-911X
1524-4563
Dallas
TX
[en] angiotensin-converting enzyme ; diabetes mellitus ; hypertension, renal ; microalbuminuria ; albuminuria ; Adult ; Aged ; Albuminuria/drug therapy/etiology/urine ; Antihypertensive Agents/adverse effects/therapeutic use ; Blood Pressure/drug effects ; Cough/chemically induced ; Diabetes Mellitus, Type 2/complications/physiopathology ; Dizziness/chemically induced ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Therapy, Combination ; Enalapril/adverse effects/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Indapamide/adverse effects/therapeutic use ; Male ; Middle Aged ; Perindopril/adverse effects/therapeutic use ; Treatment Outcome
[en] Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP > or =140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59+/-9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 microg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3.0 [95% CI -5.6, -0.4], P=0.012; systolic BP -1.5 [95% CI -3.0, -0.1] diastolic BP P=0.019) and AER -42% (95% CI -50%, -33%) versus -27% (95% CI -37%, -16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection.
Students ; Researchers ; Professionals
http://hdl.handle.net/2268/2077
also: http://hdl.handle.net/2268/12589
10.1161/01.HYP.0000064943.51878.58
http://hyper.ahajournals.org/cgi/content/full/41/5/1063

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Scheen_A_2003_hyp_1063.pdfPublisher postprint301.52 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.